| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/09/2000 | EP0977845A1 Human sodium-dependent phosphate cotransporter |
| 02/09/2000 | EP0977843A1 Novel human transmembrane 4 superfamily protein |
| 02/09/2000 | EP0977834A2 Human serine protease precursor |
| 02/09/2000 | EP0977777A1 A novel th2-specific gene |
| 02/09/2000 | EP0977733A1 Arylsulfonylamino hydroxamic acid derivatives |
| 02/09/2000 | EP0977597A4 Improved methods for diagnostic imaging using a contrast agent and a vasodilator |
| 02/09/2000 | EP0977597A1 Improved methods for diagnostic imaging using a contrast agent and a vasodilator |
| 02/09/2000 | EP0977593A1 Embolus therapy using insoluble microparticles or vesicles containing contrast agents |
| 02/09/2000 | EP0977586A1 Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| 02/09/2000 | EP0977585A1 Methods for diagnosing and treating body weight related disorders in animals |
| 02/09/2000 | EP0977582A1 Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 02/09/2000 | EP0977578A1 Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 02/09/2000 | EP0977577A1 Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant |
| 02/09/2000 | EP0977575A1 THE USE OF $g(a)-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES |
| 02/09/2000 | EP0977574A1 Methods for in vivo reduction of cyanide levels and compositions useful therefor |
| 02/09/2000 | EP0977573A1 Use of an nk-1 receptor antagonist and an ssri for treating obesity |
| 02/09/2000 | EP0977572A1 Use of nk-1 receptor antagonists for treating eating disorders |
| 02/09/2000 | EP0977570A1 Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating aids |
| 02/09/2000 | EP0977563A1 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 02/09/2000 | EP0977559A1 Enhanced anti-cancer agent delivery to solid tumors by primer compounds |
| 02/09/2000 | EP0977558A2 Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
| 02/09/2000 | EP0977482A1 IDENTIFICATION OF POLYNUCLEOTIDES ENCODING NOVEL $i(HELICOBACTER) POLYPEPTIDES IN THE $i(HELICOBACTER) GENOME |
| 02/09/2000 | EP0746332B1 Dna encoding a human neuropeptide y/peptide yy/pancreatic polypeptide receptor (y4) and uses thereof |
| 02/09/2000 | CN1244213A Pressure-mediated intracellular delivery of molecules or microparticles |
| 02/09/2000 | CN1244123A Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimdazole, and optionally a protentiator |
| 02/09/2000 | CN1244122A Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| 02/08/2000 | US6022897 Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| 02/08/2000 | US6022878 Inhibitors of rotamase enzyme activity |
| 02/08/2000 | US6022866 Use of hyaluronic acid and forms to prevent arterial restenosis |
| 02/08/2000 | US6022860 Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation |
| 02/08/2000 | US6022694 Assay for ligands to tyrosine kinase receptors |
| 02/08/2000 | US6022541 Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
| 02/08/2000 | US6022538 Administering adriamycin or cisplatin, and cell therapy cells modified by in vitro treatment with a cytokine and gamma irradiation at a dose to irreversibly arrest cell proliferation but not interfere with the cytotoxic activity |
| 02/08/2000 | US6022527 Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof |
| 02/08/2000 | US6022311 Apparatus and method for a custom soft-solid hearing aid |
| 02/08/2000 | CA2271571C Improved phase separation-microencapsulated pharmaceutical compositions useful for alleviating dental disease |
| 02/03/2000 | WO2000005407A2 DUPLICATIONS OF HUMAN CHROMOSOME 15q24-25 AND ANXIETY DISORDERS, DIAGNOSTIC METHODS FOR THEIR DETECTION |
| 02/03/2000 | WO2000005375A1 Gbs toxin receptor |
| 02/03/2000 | WO2000005374A2 Molecules associated with cell proliferation |
| 02/03/2000 | WO2000005362A1 Mekk1(serine threonine kinases)-interacting fha (forkhead associated domain) protein 1 (mif1) |
| 02/03/2000 | WO2000005361A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 02/03/2000 | WO2000005259A1 Secreted cysteine rich protein-6 (scrp-6) |
| 02/03/2000 | WO2000005244A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |
| 02/03/2000 | WO2000004923A1 Scrp-5: secreted cysteine rich protein-5 |
| 02/03/2000 | WO2000004899A1 Ophthalmic compositions for treating ocular hypertension |
| 02/03/2000 | WO2000004898A1 Ophthalmic compositions for treating ocular hypertension |
| 02/03/2000 | WO2000004897A1 Bioimplant formulation |
| 02/03/2000 | WO2000004892A2 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 02/03/2000 | WO2000004890A1 Use of glucose uptake enhancer for reducing apoptosis |
| 02/03/2000 | WO2000004889A1 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 02/03/2000 | WO2000004888A2 Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury |
| 02/03/2000 | WO2000004884A1 Pharmaceutical preparations for the topical treatment of mucocutaneous herpes infections and herpetic keratitis of the eye |
| 02/03/2000 | WO2000004878A1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy |
| 02/03/2000 | WO1999065517A3 Therapeutic compositions that produce an immune response by altering the antigen |
| 02/03/2000 | WO1999064464A3 Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
| 02/03/2000 | WO1999064001A3 Methods and compositions for increasing penetration of hiv protease inhibitors |
| 02/03/2000 | WO1999063936A3 Novel therapeutic agents that modulate endothelin receptors |
| 02/03/2000 | WO1999063933A3 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 02/03/2000 | WO1999063932A3 Multibinding agents that modulate the 5-ht transporter |
| 02/03/2000 | WO1999059620A9 Angiostatin receptor |
| 02/03/2000 | WO1999058947A3 Modulation of molecular interaction sites on rna and other biomolecules |
| 02/03/2000 | WO1999054349A3 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 02/03/2000 | DE19834820A1 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil |
| 02/03/2000 | DE19834819A1 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil |
| 02/03/2000 | DE19834507A1 Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil Pharmaceutical, water-soluble tablet formulation for use of sildenafil |
| 02/03/2000 | DE19834506A1 Transmucosales therapeutisches System zur Anwendung von Sildenafil Transmucosal therapeutic system for the administration of sildenafil |
| 02/03/2000 | DE19834505A1 Transdermal therapeutic system useful for treating male sexual impotence contains sildenafil |
| 02/03/2000 | DE19834047A1 Substituierte Pyrazolderivate Substituted pyrazole derivatives |
| 02/03/2000 | DE19834045A1 (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin (4-amino-5-ethylpyrimidine-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine |
| 02/03/2000 | DE19834044A1 Neue substituierte Pyrazolderivate New substituted pyrazole derivatives |
| 02/03/2000 | CA2338216A1 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 02/03/2000 | CA2338211A1 Use of glucose uptake enhancer for reducing apoptosis |
| 02/03/2000 | CA2337399A1 Ophthalmic compositions for treating ocular hypertension |
| 02/03/2000 | CA2337349A1 Ophthalmic compositions for treating ocular hypertension |
| 02/03/2000 | CA2335653A1 Molecules associated with cell proliferation |
| 02/03/2000 | CA2335062A1 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 02/02/2000 | EP0976747A2 Use of 5HT-1F receptor antagonists for treating anxiety disorders |
| 02/02/2000 | EP0976404A2 A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal |
| 02/02/2000 | EP0975963A1 Prostate specific antigen substrates |
| 02/02/2000 | EP0975954A1 Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
| 02/02/2000 | EP0975809A1 Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication |
| 02/02/2000 | EP0975775A2 Regulatory system for inducible expression of genes with lambdoid promoters |
| 02/02/2000 | EP0975769A1 Novel prostate-associated kallikrein |
| 02/02/2000 | EP0975756A1 Fibroblasts with a foreign gene-containing composition for treating wounds |
| 02/02/2000 | EP0975751A1 A tm4sf human tumor-associated antigen |
| 02/02/2000 | EP0975680A1 Interactive system for substance presentation and elimination |
| 02/02/2000 | EP0975649A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
| 02/02/2000 | EP0975380A2 Membrane system for controlled tissue regeneration in cases of diseases of the peridontium |
| 02/02/2000 | EP0975366A1 Cytoprotective agents comprising monoamine oxidase inhibitors |
| 02/02/2000 | EP0975365A1 Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis or growth of dms |
| 02/02/2000 | EP0975362A2 Pharmaceutical or food composition for treating pathologies related to graft versus host, allergic or autoimmune reaction |
| 02/02/2000 | EP0975361A1 Methods of modulating immune coagulation |
| 02/02/2000 | EP0975359A1 Potentiation of the immune response through delivery of compounds binding a cytoplasmic dipeptidase |
| 02/02/2000 | EP0975356A1 Pulsatile delivery of leptin receptor ligands |
| 02/02/2000 | EP0975355A2 Hexameric fusion proteins and uses therefor |
| 02/02/2000 | EP0975347A1 Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
| 02/02/2000 | EP0975343A1 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
| 02/02/2000 | EP0975341A1 Synergistic antitumor composition containing a naphthalensulphonic acid derivative |
| 02/02/2000 | EP0975327A1 Use of 5ht3 antagonists for promoting intestinal lavage |
| 02/02/2000 | EP0592557B1 Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |